- Home
- TOP vs SCYX Comparison
TOP vs SCYX Comparison
Compare TOP & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TOP | SCYX |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.8M | 32.6M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TOP | SCYX |
|---|---|---|
| Price | $1.03 | $0.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 62.0K | ★ 336.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $257,000.00 |
| Revenue This Year | N/A | $170.77 |
| Revenue Next Year | N/A | $286.38 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.94 | $0.57 |
| 52 Week High | $3.33 | $1.29 |
Technical Indicators
Market Signals| Indicator | TOP | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 43.87 | 57.56 |
| Support Level | $1.00 | $0.69 |
| Resistance Level | $1.13 | $0.88 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 8.00 | 69.63 |
Price Performance
Historical ComparisonAbout TOP TOP Financial Group Limited
TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.